QLS-111 + latanoprost

QLS-111 + latanoprost is a **novel fixed-dose combination eye drop** in clinical development for the treatment of primary open-angle glaucoma (POAG), normal-tension glaucoma (NTG), and ocular hypertension (OHT)[1][2][5]. This **preservative-free combination** consists of QLS-111, an ATP-sensitive potassium channel modulator that selectively reduces episcleral venous pressure (EVP), and latanoprost, a prostaglandin analogue that increases uveoscleral outflow. By targeting two distinct and complementary mechanisms—EVP reduction (addressing distal outflow resistance) and enhanced uveoscleral outflow—the combination aims to achieve greater intraocular pressure (IOP) reduction than either agent alone, maximizing IOP control for patients who cannot achieve target levels with current therapies[1][2][5].

Brand names

QLS-111-FDCQLS111-FDCQLS 111-FDC

Other names

QLS-111 fixed-dose combinationQLS111 fixed-dose combinationQLS 111 fixed-dose combinationQLS-111 and latanoprost fixed-dose combinationQLS111 and latanoprost fixed-dose combinationQLS 111 and latanoprost fixed-dose combination